Certificate of Analysis records, third-party testing confirmation, and lot traceability files form the minimum documentation set before a batch clears institutional intake review. Batch documentation requirements have become more specific as institutional procurement processes have matured. KPV and inflammation research protocols depend on compound consistency across the full study duration, and the documentation attached to each batch is the mechanism through which procurement teams verify that consistency before the compound enters a protocol. If a supplier treats document as secondary to the product itself at the qualification stage, then they will be removed from consideration for supplying the product. Research-active organizations have their own procurement frameworks that vary from institution to institution, but several elements appear to be consistent among procurement frameworks at research-active organizations as a whole.
Certificate of Analysis requirements
Batch documentation review starts with the Certificate of Analysis. The procurement team examines the purity percentage, the analytical method, batch number, and production date, as well as the laboratory where it was tested. Certificates that list purity without specifying the analytical method do not meet most institutional review requirements since the figure cannot be interpreted independently. Institutions running multi-phase protocols also compare the Certificate across consecutive batches rather than reviewing each in isolation. A pattern of purity variation across batches, even within acceptable tolerance ranges, signals a production process that may not hold over the protocol duration and warrants further investigation before bulk commitment.
Third-party testing records
Third-party testing records confirm that an independent laboratory analysed the batch and found results consistent with the supplier’s Certificate of Analysis. The key requirement is independence: the testing laboratory must have no commercial relationship with the supplier. Some institutions maintain a list of approved third-party testing facilities, and suppliers whose testing was conducted by a laboratory not on that list may need to arrange supplementary testing before the batch is accepted.
The scope of third-party testing required varies by compound and protocol. For inflammatory pathway research, teams typically require:
- Purity confirmation by HPLC or mass spectrometry.
- Identity verification confirming the compound matches its stated molecular structure.
- Residual solvent analysis where the production process involves solvent use.
- Microbial testing where the compound will be used in cell culture or animal model protocols.
Lot traceability and stability documentation
Lot traceability records link each batch to its production date, raw material inputs, and in-process quality check results. This record becomes relevant when a batch produces unexpected results in a protocol and the research team needs to determine whether the issue is compound-related or experimental. Without traceability records, that determination cannot be made from the documentation alone. A stability document confirms the compound’s purity under the storage conditions specified by the supplier over the claimed shelf life period. Extended protocols require stability data covering the entire anticipated storage period; optional supplements are not allowed.
Batch documentation requirements reflect research programmes’ practical needs, not administrative preferences. Procurement teams need complete documentation to qualify suppliers for standing orders, protect the research record, and comply with audit requirements.
